Prytime Medical is a commercial-stage medical device company focused on life-saving hemorrhage control. Its core product line centers on REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) catheters, including the ER-REBOA™ PLUS and the newer pREBOA-PRO™, designed for temporary aortic occlusion in trauma and obstetric emergencies. The company has established a global commercial footprint with distribution partners and emphasizes comprehensive clinical training through its REBOA Academy. Prytime operates in a high-stakes, niche segment of the medical device market, addressing a leading cause of potentially survivable death in trauma.
TraumaObstetric HemorrhageEmergency Medicine
Technology Platform
Catheter-based systems for Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA), featuring balloon catheters for complete or partial aortic occlusion to control non-compressible truncal hemorrhage.
Funding History
2
Total raised:$30M
Series B$20MSante Ventures
Series A$10MSante Ventures
Opportunities
The primary opportunity lies in addressing the leading cause of potentially survivable death in trauma through a minimally invasive technique.
Expansion into obstetric hemorrhage (postpartum hemorrhage) and pre-hospital/military settings represents significant new market avenues.
Technological leadership with partial REBOA (pREBOA-PRO™) could establish a new standard of care and create a competitive moat.
Risk Factors
Adoption is limited by the procedural complexity and required training, posing a significant market education hurdle.
Competition from larger medical device companies entering the REBOA space is a constant threat.
The company is also exposed to regulatory, reimbursement, and liability risks inherent to high-acuity medical devices.
Competitive Landscape
Prytime operates in the niche but growing market for REBOA devices. Competition includes other specialized medical device firms offering REBOA catheters (e.g., devices from larger companies like Cook Medical or Terumo). The competitive landscape is defined by technological features (e.g., partial occlusion capability), ease of use, clinical evidence, and the strength of training and support programs.
